BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis.
Sanderson, M.P., Apgar, J., Garin-Chesa, P., Hofmann, M.H., Kessler, D., Quant, J., Savchenko, A., Schaaf, O., Treu, M., Tye, H., Zahn, S.K., Zoephel, A., Haaksma, E., Adolf, G.R., Kraut, N.(2015) Mol Cancer Ther 14: 2762-2772
- PubMed: 26438154 
- DOI: 10.1158/1535-7163.MCT-15-0539
- Primary Citation of Related Structures:  
5E1S - PubMed Abstract: 
Inhibition of the IGF1R, INSRA, and INSRB receptor tyrosine kinases represents an attractive approach of pharmacologic intervention in cancer, owing to the roles of the IGF1R and INSRA in promoting cell proliferation and survival. However, the central role of the INSRB isoform in glucose homeostasis suggests that prolonged inhibition of this kinase could result in metabolic toxicity ...